Palleon Pharmaceuticals

Palleon Pharmaceuticals is at the forefront of glycobiology-based drug discovery, developing first-in-class therapies that degrade cell surface sialoglycans to treat cancer and autoimmune diseases. Its core technology, the EAGLE platform, fuses human sialidase enzymes with targeting antibodies to selectively remove immunosuppressive sugar molecules from diseased cells, rendering them vulnerable to immune attack. The company has advanced programs in both oncology (E-688) and immunology (E-602), supported by a strategic collaboration with Henlius. Palleon represents a private, preclinical-stage biotech targeting a significant new frontier in immuno-oncology and inflammation.

EAGLE (Enzyme-Antibody Glycan Editing) platform: a proprietary technology that creates novel biologic drugs by genetically fusing human sialidase enzymes with human monoclonal antibodies to selectively degrade immunosuppressive sialoglycans on the surface of pathogenic cells.

Competition in glycobiology is emerging but still nascent. Palleon's most direct competitors are other biotechs exploring sialic acid biology (e.g., sialidase fusions, Siglec blockers). More broadly, it competes with all developers of next-generation immuno-oncology agents and novel autoimmune therapies. Its proprietary EAGLE platform and foundational IP provide a potential competitive moat.